At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
Displaying 151–160 of 615 results.
-
Researchers want to find the best schedule for giving a new vaccine to people with neuroblastoma. The people in this study have neuroblastoma that is in remission (no signs of cancer). In addition, their cancers have a strong chance of coming back (high risk). The vaccine is given with a naturally occurring substance called beta-glucan.
-
Metaiodobenzylguanidine (MIBG) is a substance taken up specifically by neuroblastoma, pheochromocytoma, or paraganglioma tumor cells. MIBG can be combined with radioactive iodine (131I) in the laboratory to form the radioactive compound 131I-MIBG. The 131I-MIBG compound concentrates more in cancer cells than in normal cells. It may therefore deliver more radiation directly to cancer cells while sparing normal organs.
-
Researchers want to find the best dose of LY4052031 to treat people with advanced solid tumors. The people in this study have metastatic solid tumors that came back or keep growing after treatment. In addition, their tumors make a protein called Nectin-4, which plays a role in cancer growth.
-
The standard treatment for head and neck cancers includes high-dose radiation therapy and chemotherapy, but it commonly causes side effects. In this study, researchers are assessing a treatment for head and neck cancer that starts with standard high-dose radiation therapy and chemotherapy and then reduces the doses of both treatments. Patients then have surgery to remove lymph nodes and tissue from the neck area.
-
Researchers are comparing taletrectinib with a placebo (inactive drug) in people with non-small cell lung cancer (NSCLC). The people in this study have stage 1B-3A NSCLC that has a ROS1 gene fusion. They have had the tumor completely removed with surgery.
-
The purpose of this study is to find the highest dose of the investigational drug PC14586 that can be given in patients with solid tumors that came back or continue to grow despite prior therapy and contain a mutation in the TP53 gene. The p53 protein produced by this gene normally tells cells when to stop dividing, but when TP53 is altered (mutated), cancer may result.
-
This study is assessing the safety and effectiveness of ASTX727 in people who have malignant peripheral nerve sheath tumors (MPNST) with a mutation in a gene complex called PRC2 (EED or SUZ12). ASTX727 is a combination of two drugs (cedazuridine and decitabine) that have been designed to target cancer cells with a PRC2 complex genetic mutation and disrupt the cells' ability to survive and grow.
-
The purpose of this study is to find the highest dose of the investigational drug AVA6000 that can be given safely in people with advanced solid tumors that are not responding to treatment. AVA6000 is very similar to a standard chemotherapy drug called doxorubicin. Like doxorubicin, AVA6000 works to slow or stop the growth of cancer cells by blocking an enzyme. Unlike doxorubicin, however, AVA6000 is a "prodrug," meaning it remains inactive until it reaches the site of the cancer. Because of the way AVA6000 works, it may be useful for treating cancer with fewer side effects than doxorubicin. AVA6000 is given intravenously (by vein).
-
Researchers want to see if a test for cancer DNA in the blood helps doctors decide whether to reduce Hodgkin lymphoma chemotherapy. The blood test is a circulating tumor DNA (ctDNA) test called Foresight CLARITY. ctDNA is genetic material released by tumor cells directly into the bloodstream.
-
After a stem cell transplant, some patients develop a condition called graft-versus-host disease (GVHD). This occurs when the donor's healthy immune cells see the recipient's normal cells as foreign and begin to attack them.